EndoPredict^® in early hormone receptor-positive, HER2-negative breast cancer.

ABSTRACT:

Purpose

Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict^® on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test.

Methods

Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated between 2011 and 2016 were included in this study to investigate the role of EndoPredict^® (EPclin) in the treatment of early breast cancer. A main study aim was to analyze the changes in therapy recommendations with and without EPclin. In addition, the impact of clinico-pathological parameters for the decision to perform EPclin was examined by Pearson's chi-squared test (χ²-test) an

SUBMITTER: Almstedt K 

PROVIDER: S-EPMC7275019 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature